Peptic Ulcer Therapeutics- Pipeline Assessment and Market Forecasts to 2018

NEW YORK, Feb. 7, 2012 /PRNewswire/ -- Reportlinker.com announces that a new market research report is available in its catalogue:

http://www.reportlinker.com/p0704132/Peptic-Ulcer-Therapeutics--Pipeline-Assessment-and-Market-Forecasts-to-2018.html#utm_source=prnewswire&utm_medium=pr&utm_campaign=Therapy

Peptic Ulcer Therapeutics- Pipeline Assessment and Market Forecasts to 2018

- Annualized seven key markets (US, France, Germany, Italy, Spain, UK and Japan) Peptic Ulcer Therapeutics market revenues data from 2005 to 2009, forecast for eight years to 2018.

- Pipeline analysis data providing a split across the different phases, mechanisms of action being developed and emerging trends by seven key markets. Pipeline candidates fall under major therapeutic classes.

- Analysis of the current and future competition in the seven key countries Peptic Ulcer Therapeutics market.

- Insightful review of the key industry drivers, restraints and challenges. Each trend is independently researched to provide a qualitative analysis of its implications.

- Key topics covered include strategic competitor assessment, market characterization, unmet needs and the implications for the Peptic Ulcer Therapeutics market.

- Analysis of key recent licensing and partnership agreements in Peptic Ulcer Therapeutics market

- Develop and design your in-licensing and out-licensing strategies through a review of pipeline products and technologies and by identifying the companies with the most robust pipeline.

- Develop business strategies by understanding the trends shaping and driving the global Peptic Ulcer Therapeutics market.

- Drive revenues by understanding the key trends, innovative products and technologies, market segments and companies likely to impact the global Peptic Ulcer Therapeutics market in future.

- Formulate effective sales and marketing strategies by understanding the competitive landscape and by analyzing the performance of various competitors.

- Identify emerging players with potentially strong product portfolios and create effective counter-strategies to gain a competitive advantage.

- Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments and strategic partnerships.

- What's the next big thing in the global Peptic Ulcer Therapeutics market landscape? – Identify, understand and capitalize.

1 Table of Contents1 Table of Contents 31.1 List of Tables 51.2 List of Figures 62 Peptic Ulcer Therapeutics - Introduction 72.1 Disease Overview 72.1.1 Complications 82.2 Epidemiology 82.2.1 Prevalence/Incidence 82.2.2 Trends in Prevalence/Incidence 92.2.3 Mortality 92.3 Etiology and Pathophysiology 92.3.1 H. pylori Infection 92.3.2 Use of NSAIDs 102.3.3 Other Causes and Risk Factors 112.4 Signs and Symptoms 122.5 Diagnosis 122.5.1 Noninvasive Techniques 122.5.2 Invasive Techniques 132.6 Treatment and Management Options 132.6.1 Treatment of H. pylori-Induced Peptic Ulcer 132.6.2 Treatment of NSAID-Induced Peptic Ulcer 142.6.3 Treatment of Ulcer Complications 142.7 GlobalData Pipeline Report Guidance 153 Peptic Ulcer Therapeutics - Market Characterization 163.1 Peptic Ulcer Therapeutics Market Size (2005-2010) - Global 163.2 Peptic Ulcer Therapeutics Market Forecast (2010-2018) - Global 173.3 Peptic Ulcer Therapeutics Market Size (2005-2010) - The US 183.4 Peptic Ulcer Therapeutics Market Forecast (2010-2018) - The US 193.5 Peptic Ulcer Therapeutics Market Size (2005-2010) - France 203.6 Peptic Ulcer Therapeutics Market Forecast (2010-2018) - France 213.7 Peptic Ulcer Therapeutics Market Size (2005-2010) - Germany 223.8 Peptic Ulcer Therapeutics Market Forecast (2010–2018) - Germany 233.9 Peptic Ulcer Therapeutics Market Size (2005-2010) - Italy 243.10 Peptic Ulcer Therapeutics Market Forecast (2010–2018) - Italy 253.11 Peptic Ulcer Therapeutics Market Size (2005–2010) - Spain 263.12 Peptic Ulcer Therapeutics Market Forecast (2010-2018) - Spain 273.13 Peptic Ulcer Therapeutics Market Size (2005-2010) - The UK 283.14 Peptic Ulcer Therapeutics Market Forecast (2010–2018) - The UK 293.15 Peptic Ulcer Therapeutics Market Size (2005-2010) - Japan 303.16 Peptic Ulcer Therapeutics Market Forecast (2010–2018) - Japan 313.17 Drivers and Barriers for the Peptic Ulcer Therapeutics Market 323.17.1 Drivers for the Peptic Ulcer Therapeutics Market 323.17.2 Barriers for the Peptic Ulcer Therapeutics Market 323.18 Opportunity and Unmet Need Analysis 323.19 Key Takeaway 334 Peptic Ulcer Therapeutics - Competitive Assessment 344.1 Overview 344.2 Key Brands in the Peptic Ulcer Therapeutics Market 344.3 Strategic Competitor Assessment 354.4 Product Profiles for the Major Marketed Products in the Peptic Ulcer Therapeutics Market 354.4.1 Nexium (esomeprazole magnesium) 354.4.2 Vimovo (naproxen/esomeprazole magnesium) 384.4.3 Pariet/Aciphex (rabeprazole sodium) 394.5 Key Takeaway 405 Peptic Ulcer Therapeutics - Pipeline Assessment 415.1 Overview 415.2 Strategic Pipeline Assessment 415.3 Peptic Ulcer Therapeutics Pipeline - Pipeline by Phases of Development 415.3.1 Peptic Ulcer Therapeutics - Filed Pipeline 425.3.2 Peptic Ulcer Therapeutics - Phase III Pipeline 425.3.3 Peptic Ulcer Therapeutics - Phase II Pipeline 425.3.4 Peptic Ulcer Therapeutics - Pre-Clinical Pipeline 425.3.5 Technology Trends Analytic Framework 435.4 Peptic Ulcer Therapeutics Market - Clinical Pipeline by Mechanism of Action 455.5 Peptic Ulcer Therapeutics - Promising Drugs under Clinical Development 455.6 Molecule Profile for Promising Drugs under Clinical Development 465.6.1 Axanum 465.6.2 PA32540 465.7 Key Takeaway 476 Peptic Ulcer Therapeutics - Clinical Trials Mapping 486.1 Clinical Trials by Region/Country (The US, EU5 and Japan) 486.2 Clinical Trials by Phase 496.3 Clinical Trials by Trial Status 506.4 Prominent Sponsors 516.5 Top Companies Participating in Peptic Ulcer Therapeutics Clinical Trials 537 Strategic Assessment 547.1 Key Events Impacting the Future Market 547.2 Peptic Ulcer Therapeutics: Implications for Future Market Competition 558 Peptic Ulcer Therapeutics - Future Players 568.1 Introduction 568.2 Company Profiles 568.2.1 AstraZeneca 568.2.2 Pozen 588.2.3 Other Companies 609 Peptic Ulcer Therapeutics - Licensing and Partnership Deals 6110 Peptic Ulcer Therapeutics - Appendix 6310.1 Market Definitions 6310.2 Abbreviations 6310.3 Methodology 6410.3.1 Coverage 6410.3.2 Secondary Research 6410.3.3 Forecasting 6510.3.4 Primary Research 6710.3.5 Expert Panel Validation 6710.4 Contact Us 6710.5 Disclaimer 6710.6 Bibliography 68

List of Tables

Table 1: Peptic Ulcer Therapeutics Market, Global, Revenue ($m), 2005-2010 16Table 2: Peptic Ulcer Therapeutics Market, Global, Forecasts ($m), 2010-2018 17Table 3: Peptic Ulcer Therapeutics Market, The US, Revenue ($m), 2005-2010 18Table 4: Peptic Ulcer Therapeutics Market, The US, Forecasts ($m), 2010-2018 19Table 5: Peptic Ulcer Therapeutics Market, France, Revenue ($m), 2005-2010 20Table 6: Peptic Ulcer Therapeutics Market, France, Forecasts ($m), 2010-2018 21Table 7: Peptic Ulcer Therapeutics Market, Germany, Revenue ($m), 2005-2010 22Table 8: Peptic Ulcer Therapeutics Market, Germany, Forecasts ($m), 2010-2018 23Table 9: Peptic Ulcer Therapeutics Market, Italy, Revenue ($m), 2005-2010 24Table 10: Peptic Ulcer Therapeutics Market, Italy, Forecasts ($m), 2010-2018 25Table 11: Peptic Ulcer Therapeutics Market, Spain, Revenue ($m), 2005-2010 26Table 12: Peptic Ulcer Therapeutics Market, Spain, Forecasts ($m), 2010-2018 27Table 13: Peptic Ulcer Therapeutics Market, The UK, Revenue ($m), 2005-2010 28Table 14: Peptic Ulcer Therapeutics Market, The UK, Forecasts ($m), 2010-2018 29Table 15: Peptic Ulcer Therapeutics Market, Japan, Revenue ($m), 2005-2010 30Table 16: Peptic Ulcer Therapeutics Market, Japan, Forecasts ($m), 2010-2018 31Table 17: Key Drugs in the Peptic Ulcer Therapeutics Market 34Table 18: Efficacy of Nexium 36Table 19: Clinical Studies of Nexium 37Table 20: Efficacy of Vimovo 38Table 21: Common Treatment Emergent Adverse Events Associated with Vimovo 38Table 22: Clinical Studies of Vimovo 38Table 23: Efficacy of Aciphex 39Table 24: Clinical Studies of Aciphex 40Table 25: Peptic Ulcer Therapeutics, Filed Pipeline, 2011 42Table 26: Peptic Ulcer Therapeutics, Phase III Pipeline, 2011 42Table 27: Peptic Ulcer Therapeutics, Phase II Pipeline, 2011 42Table 28: Peptic Ulcer Therapeutics, Pre-Clinical Pipeline, 2011 42Table 29: Peptic Ulcer Therapeutics, Most Promising Drugs under Clinical Development, 2011 45Table 30: Peptic Ulcer Therapeutics, Clinical Trials by Country, 2011 48Table 31: Peptic Ulcer Therapeutics, Clinical Trials by Phase, 2011 49Table 32: Peptic Ulcer Therapeutics, Clinical Trials by Status (%), 2011 50Table 33: Peptic Ulcer Therapeutics, Prominent Sponsors, 2011 52Table 34: Peptic Ulcer Therapeutics, Top Companies Participating in Clinical Trials, 2011 53Table 35: AstraZeneca, Peptic Ulcer Pipeline, 2011 58Table 36: Pozen, Peptic Ulcer Pipeline, 2011 59Table 37: Peptic Ulcer Therapeutics Market, Future Players 60Table 38: Peptic Ulcer Therapeutics, Global, Deals, 2009-2011 61

List of Figures

Figure 1: Peptic Ulcer Therapeutics, Types of Peptic Ulcer 7Figure 2: Peptic Ulcer Therapeutics, Pathophysiology of NSAID-Induced Peptic Ulcer 10Figure 3: Peptic Ulcer Therapeutics, Pathophysiology 11Figure 4: Treatment Algorithm for NSAID-Induced Peptic Ulcer 14Figure 5: Peptic Ulcer Therapeutics Market, Global, Revenue ($m), 2005-2010 16Figure 6: Peptic Ulcer Therapeutics Market, Global, Forecast ($m), 2010-2018 17Figure 7: Peptic Ulcer Therapeutics Market, The US, Revenue ($m), 2005-2010 18Figure 8: Peptic Ulcer Therapeutics Market, The US, Forecast ($m), 2010-2018 19Figure 9: Peptic Ulcer Therapeutics Market, France, Revenue ($m), 2005-2010 20Figure 10: Peptic Ulcer Therapeutics Market, France, Forecast ($m), 2010-2018 21Figure 11: Peptic Ulcer Therapeutics Market, Germany, Revenue ($m), 2005-2010 22Figure 12: Peptic Ulcer Therapeutics Market, Germany, Forecast ($m), 2010-2018 23Figure 13: Peptic Ulcer Therapeutics Market, Italy, Revenue ($m), 2005-2010 24Figure 14: Peptic Ulcer Therapeutics Market, Italy, Forecast ($m), 2010-2018 25Figure 15: Peptic Ulcer Therapeutics Market, Spain, Revenue ($m), 2005-2010 26Figure 16: Peptic Ulcer Therapeutics Market, Spain, Forecast ($m), 2010-2018 27Figure 17: Peptic Ulcer Therapeutics Market, The UK, Revenue ($m), 2005-2010 28Figure 18: Peptic Ulcer Therapeutics Market, The UK, Forecast ($m), 2010-2018 29Figure 19: Peptic Ulcer Therapeutics Market, Japan, Revenue ($m), 2005-2010 30Figure 20: Peptic Ulcer Therapeutics Market, Japan, Forecast ($m), 2010-2018 31Figure 21: Opportunity and Unmet Need in the Peptic Ulcer Therapeutics Market, 2010 33Figure 22: Peptic Ulcer Therapeutics, Strategic Competitor Assessment, 2010 35Figure 23: Peptic Ulcer Therapeutics, Pipeline by Phase of Development, 2011 41Figure 24: Peptic Ulcer Therapeutics, Technology Trends Analytics Framework, 2011 43Figure 25: Peptic Ulcer Therapeutics, Technology Trends Analytics Framework, Description, 2011 44Figure 26: Peptic Ulcer Therapeutics, Pipeline by Mechanism of Action (%), 2011 45Figure 27: Peptic Ulcer Therapeutics, Efficacy of PA32540 47Figure 28: Peptic Ulcer Therapeutics, Clinical Trials by Country, 2011 48Figure 29: Peptic Ulcer Therapeutics, Clinical Trials by Phase (%), 2011 49Figure 30: Peptic Ulcer Therapeutics, Clinical Trials by Status (%), 2011 50Figure 31: Peptic Ulcer Therapeutics, Overall Sponsors (%), 2011 51Figure 32: Peptic Ulcer Therapeutics, Prominent Sponsors (%), 2011 52Figure 33: Peptic Ulcer Therapeutics, Top Companies Participating in Clinical Trials, 2011 53Figure 34: Peptic Ulcer Therapeutics Market, Drivers and Restraints, 2011 54Figure 35: Implications for Future Market Competition in the Peptic Ulcer Market, 2011 55Figure 36: Peptic Ulcer Therapeutics Market, Pipeline by Company, 2011 56Figure 37: GlobalData Market Forecasting Model 66

Companies mentioned

AstraZenecaPozen

More  

Check our  

Nicolas Bombourg
Reportlinker
Email: [email protected]
US: (805)652-2626
Intl: +1 805-652-2626

SOURCE Reportlinker